



**Prof. Dr. med. Stephan Mielke**

Geschäftsführender Oberarzt der Med. Klinik II  
Direktor des Stammzelltransplantationsprogramms

Universitätsklinikum Würzburg  
Zentrum Innere Medizin (ZIM)  
Medizinische Klinik und Poliklinik II  
Abteilung Hämatologie und Onkologie  
Oberdürrbacher Str. 6  
D-97080 Würzburg  
Germany

Dr Mielke graduated in 1999 from Georg-August University Medical School in Göttingen, Germany. After completion of his scientific thesis at the Department of Obstetrics and Gynecology he received his doctoral degree from Georg-August University. He started his residency and fellowship program at the Albert Ludwig University of Freiburg in Germany, Department of Internal Medicine, Division of Hematology and Oncology. In 2003 he was awarded a postdoctoral grant from the Dr.-Mildred-Scheel-Stiftung in Germany to carry out translational research at the National Institutes of Health. From May 2004 to August 2007 Dr Mielke worked in the Allotransplantation Section of the Hematology Branch at the NIH, Bethesda, MD, USA. Afterwards he joined the Department of Internal Medicine II at the Julius-Maximilian University of Würzburg in Germany where he carries responsibilities as attending internist since 2008. As a specialist for Hematology and Oncology he focuses on allogeneic hematopoietic stem cell transplantation from matched and mismatched donors, immunotherapy and optimized solid tumor therapy. He wrote a professorial thesis about selective T cell depletion strategies in allogeneic stem cell transplantation and received his habilitation in 2009. In 2011 he became director of the Adult Allogeneic Stem Cell Transplant Program and headed the successful JACIE-based accreditation process in 2013. Since 2012 he acts as a deputy director of the Department of Internal Medicine II. In 2014 he was announced professor at the Medical Faculty of the University of Würzburg.

Dr. Mielke has published 50 peer-reviewed articles with a cumulative impact factor of 250 and has procured 1,2 million Euros of extramural and competitive funding. He is member of the American Society of Hematology (ASH), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cellular Therapy (ISCT) and the German Society of Hematology and Oncology (DGHO). He has been elected into the office of the European Treasurer at the ISCT for the period of 2011 to 2014. He has joined the Immunobiology working party of EBMT and the editorial boards of „Bone Marrow Transplantation“, “American Journal of Blood Research” and “Pharmacogenomics and Personalised Medicine” and is regularly invited as a peer scientific reviewer for several international journals in the field of stem cell transplantation, tumor immunology and pharmacodynamics of anti-cancer drugs.

(Last updated on Feb. 18<sup>th</sup>, 2014)